Phase i trial of m-bacod and granulocyte macrophage colony stimulating factor in hiv-associated non-hodgkin’s lymphoma

Christina Walsh, James C. Wernz, Alexandra Levine, Mark Rarick, Esther Willson, Debbie Melendez, Eric Bonnern, James Thompson, Brent Shelton

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

The use of full-dose intensive regimens of chemotherapy in patients with HIV-associated lymphoma has often resulted in severe toxicity, treatment delay, and reduced subsequent dosing. We conducted a Phase I trial to evaluate the toxicity of the combination of m-BACOD (methotrexate, Bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone) with granulocyte-macrophage colony stimulating factor (GMCSF) in these patients. A total of 17 patients were entered and treated at three dose levels of m-BACOD in combination with a fixed dose of GMCSF. Eight patients received standard dose m-BACOD plus GMCSF without experiencing dose-limiting hematologic toxicity, although significant nonhematologic toxicity was seen. We conclude that it is feasible to treat patients with HIV-associated lymphoma using standard dose m-BACOD plus GMCSF, but further study is needed to determine whether full-dose regimens improve survival when compared with reduced dose regimens in these individuals.

Original languageEnglish
Pages (from-to)265-269
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume6
Issue number3
StatePublished - Mar 1993

Keywords

  • Colony stimulating factors
  • HIV
  • Non-Hodgkin’s lymphoma

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Phase i trial of m-bacod and granulocyte macrophage colony stimulating factor in hiv-associated non-hodgkin’s lymphoma'. Together they form a unique fingerprint.

Cite this